Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback Home
Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality 54% Improvement Relative Risk ICU admission 65% Case 9% c19vitamind.com Hosseini et al. Vitamin D for COVID-19 META ANALYSIS Favors vitamin D Favors control
Hosseini, vitamin D meta analysis: 54% lower mortality [p=0.0004], 65% lower ICU admission [p=0.0003], and 9% fewer cases [p=0.11] https://c19p.org/hosseini3
copied to clipboard
Effects of Vitamin D Supplementation on COVID-19 Related Outcomes: A Systematic Review and Meta-Analysis
Hosseini et al., Nutrients, doi:10.3390/nu14102134 (meta analysis)
20 May 2022    Source   PDF   Share   Tweet
Systematic review and meta analysis showing significantly lower ICU admission and mortality with vitamin D treatment. There was no significant difference for cases.
Currently there are 82 vitamin D for COVID-19 studies, showing 37% [25‑47%] lower mortality, 32% [4‑53%] lower ventilation, 50% [27‑65%] lower ICU admission, 20% [9‑29%] lower hospitalization, and 12% [2‑21%] lower cases.
risk of death, 54.0% lower, RR 0.46, p < 0.001.
risk of ICU admission, 65.0% lower, RR 0.35, p < 0.001.
risk of case, 9.0% lower, RR 0.91, p = 0.11.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Hosseini et al., 5/20/2022, peer-reviewed, 3 authors.
Contact: banafsheh.hosseini@umontreal.ca (corresponding author), asmae.el.abd.hsj@ssss.gouv.qc.ca, francine.m.ducharme@umontreal.ca.
All Studies   Meta Analysis
This PaperVitamin DAll
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit